Exxon Mobil Corporation (XOM) or Total S.A. (ADR) (TOT)? This Supermajor Pays a Super Dividend

ConocoPhillips (NYSE:COP) spun off its downstream (refining) operations back in 2012, which now trades as Phillips 66 (check out the value in refining). The stock is now a standalone exploration and production company. ConocoPhillips is nearing completion of its three-year portfolio optimization plan and is also finishing up $9.6 billion in asset sales to help fund its $15 billion capital expenditure plan, pay dividends of $3.5 billion and $5 billion in stock buybacks.
ConocoPhillips’ $15 billion CapEx plan is one of the highest among Supermajors, but it will play a key role in its reserve replacement target of over 100%. Around 60% of CapEx is planned for North America liquids-rich plays, including its acreage portfolios in the Eagle Ford Shale, Permian Basin and Bakken Shale. ConocoPhillips pays a robust dividend yield of 4.6%, but still well below Total’s.
Don’t be fooled
Total pays the most robust dividend yield among all the Supermajors. What’s more is that it has a very reasonable payout ratio, at only 48%.
TOTAL BP Chevron Exxon Mobil ConocoPhillips
Dividend yield 6.0% 4.5% 3.1% 2.6% 4.6%
Dividend payout ratio 48% 54% 26% 23% 44%
The story gets even better. The stock is the cheapest among all Supermajors.
TOTAL BP Chevron Exxon Mobil ConocoPhillips
Forward P/E 7 8 10% 10.5 10
I like TOTAL S.A. (ADR) (NYSE:TOT)’s impressive dividend yield, especially when coupled with its “cheapness.” The stock should perform well on the back of a rebounding global economy and has over $21 billion in cash on hand, or $9.50 per share, giving it room to up its dividend over the interim.

The article This Supermajor Pays a Super Dividend originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!